基本信息 产品详情 公司简介 推荐产品
网站主页 化工产品目录 生物化工 抗体 CARD8抗体 CARD8抗体
  • CARD8抗体
  • CARD8抗体
  • CARD8抗体

1/3

CARD8抗体

Rabbit Polyclonal CARD8 Antibody
询价 20μl 起订
50μl 起订
100μl 起订
湖北 更新日期:2025-05-11

湖北瑞和宁生物科技有限公司

VIP1年
联系人:周经理
电话:027-19371278702拨打
手机:18008634902 拨打
邮箱:19384116026@163.com

产品详情:

中文名称:
CARD8抗体
英文名称:
Rabbit Polyclonal CARD8 Antibody
品牌:
艾普蒂
产地:
武汉
保存条件:
Stored at -20°C for 1876 year. Avoid repeated freeze / thaw cycles.
产品类别:
抗体
重组:
应用:
WB: IHC-P: IHC-F: ICC/IF: IP:FC:ChIP: ELISA
种属反应性:
Human,Mouse,Rat
宿主:
Rabbit
偶联物:
靶点:
CARD8

验证与应用

应用及物种
WB咨询技术 Human,Mouse,Rat
IF咨询技术 Human,Mouse,Rat
IHC1/25-1/100 Human,Mouse,Rat
ICC技术咨询 Human,Mouse,Rat
FCM咨询技术 Human,Mouse,Rat
Elisa1/1000-1/2000 Human,Mouse,Rat
   

产品详情

AliasesANF; ANP; PND; ATFB6; CDD-ANF
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman, Mouse, Rat
ImmunogenFusion protein of human NPPA
FormulationPurified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

  •  

     

       The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08023(NPPA Antibody) at dilution 1/30. (Original magnification: ×200)    


  •  

     

       The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P08023(NPPA Antibody) at dilution 1/30. (Original magnification: ×200)    


           

参考文献

以下是关于CARD8抗体的3篇代表性文献(虚拟示例,需根据实际文献验证):

1. **"CARD8 regulates NLRP3 inflammasome activation through caspase-1 interaction"**

- **作者**: Li Y et al.

- **摘要**: 研究揭示了CARD8通过结合caspase-1调控NLRP3炎症小体活化的分子机制,并开发了特异性抗体用于检测其在炎症反应中的表达变化。

2. **"Structural basis of CARD8 autoinhibition and its role in HIV protease sensing"**

- **作者**: Johnson RM et al.

- **摘要**: 利用CARD8抗体进行结构解析,阐明了CARD8的自抑制构象及其在识别HIV蛋白酶介导的细胞焦亡中的关键作用。

3. **"CARD8 expression correlates with cardiovascular disease progression"**

- **作者**: Wang H et al.

- **摘要**: 通过免疫组化分析(使用CARD8特异性抗体),发现CARD8在动脉粥样硬化患者血管组织中的表达上调,提示其与心血管炎症的潜在关联。

4. **"Antibody-based targeting of CARD8 for inflammatory disease therapy"**

- **作者**: Chen L et al.

- **摘要**: 开发了靶向CARD8的单克隆抗体,并在小鼠模型中验证其通过抑制过度炎症反应缓解类风湿性关节炎的疗效。

**注意**:以上文献标题及内容为示例性质,具体研究需查阅真实数据库(如PubMed、Google Scholar)。建议使用关键词“CARD8 antibody”或“CARD8 inflammasome”检索最新文献。

       

背景信息

CARD8 (Caspase activation and recruitment domain 8) is a protein involved in regulating inflammatory responses and apoptosis. It belongs to the CARD protein family, which mediates protein-protein interactions through its conserved CARD domain. Structurally, CARD8 contains an N-terminal pyrin domain (PYD), a central CARD domain, and a C-terminal inhibitory domain that undergoes proteasomal degradation under specific conditions. This degradation releases the N-terminal fragment, enabling its role in inflammasome activation. CARD8 interacts with NLRP3 inflammasome components and modulates caspase-1 activation, influencing the maturation of pro-inflammatory cytokines like IL-1β and IL-18.

CARD8 antibodies are research tools used to study its expression, localization, and molecular interactions in immune signaling pathways. Dysregulation of CARD8 has been implicated in autoimmune and inflammatory diseases, including rheumatoid arthritis, gout, and inflammatory bowel disease. Certain genetic polymorphisms in CARD8 are associated with altered disease susceptibility or severity, highlighting its potential as a biomarker. In therapeutic contexts, targeting CARD8 pathways may offer strategies to modulate aberrant inflammasome activity. However, its dual role in promoting or suppressing inflammation—depending on cellular context and proteolytic processing—complicates its functional characterization. Current studies employ CARD8 antibodies in techniques like Western blotting, immunofluorescence, and co-immunoprecipitation to unravel its mechanisms in health and disease. Further research is needed to clarify its tissue-specific functions and therapeutic potential.

       
CARD8抗体;CARD8;CARD8 Antibody;

公司简介

湖北瑞和宁生物科技有限公司研究创新能力, 拥有完整、科学、质量管理体系。并不断致力于技术创新,产品创新和管理创新,赢得了国内外广大用户的信任。

成立日期 (2年)
注册资本 50万(元)
员工人数 1-10人
年营业额 ¥ 100万以内
经营模式 贸易,工厂,试剂,定制,服务
主营行业 中间体,化学试剂

CARD8抗体相关厂家报价

内容声明
拨打电话 立即询价